MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
28.31
-0.55
-1.91%
After Hours: 28.12 -0.19 -0.67% 19:24 01/02 EST
OPEN
29.09
PREV CLOSE
28.86
HIGH
29.36
LOW
27.51
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
40.37
52 WEEK LOW
4.300
MARKET CAP
1.46B
P/E (TTM)
-15.7409
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CAPR last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Weekly Report: what happened at CAPR last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
Capricor Therapeutics (CAPR) Receives a Buy from Piper Sandler
TipRanks · 12/17/2025 11:57
Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Duchenne Muscular Dystrophy Therapy
Reuters · 12/16/2025 21:05
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Barchart · 12/16/2025 15:05
Capricor Therapeutics Price Target Raised to $50.00/Share From $21.00 by B. Riley Securities
Dow Jones · 12/15/2025 16:58
B. Riley Securities Reiterates Buy on Capricor Therapeutics, Raises Price Target to $50
Benzinga · 12/15/2025 16:48
CAPRICOR THERAPEUTICS INC <CAPR.O>: B. RILEY RAISES TARGET PRICE TO $50 FROM $21
Reuters · 12/15/2025 13:31
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Webull offers Capricor Therapeutics Inc stock information, including NASDAQ: CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.